12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Rasilamlo regulatory update

Germany's Federal Joint Committee (G-BA) issued a final assessment that found "no additional benefit" for Rasilamlo aliskiren/amlodipine from Novartis for patients with hypertension for whom therapy with aliskiren or amlodipine alone is not sufficient. The assessment is...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >